Lidocaine for sickle cell pain crisis in intensive care
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests whether a numbing medicine (lidocaine) given through a vein can help reduce the amount of strong painkillers (morphine or oxycodone) needed for a sickle cell pain crisis or acute chest syndrome. It aims to ease pain and possibly lower side effects from opioids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Have sickle cell disease with a common genotype (SS, SC, Sβ, or Sβ+)
- Be in intensive care for a pain crisis or acute chest syndrome
- Started strong painkillers via IV less than 72 hours before joining
- Consent to participate (or an emergency procedure if unconscious and no family available)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a low-dose of ketamine (a pain medicine) can help children and young adults with sickle cell disease who are in a pain crisis. It aims to provide better pain relief while avoiding some side effects of standard painkillers.
This study tests whether a low dose of ketamine, a pain medicine, can safely reduce pain during a sickle cell crisis in the emergency department. It aims to provide quicker pain relief for people with sickle cell disease.
This trial tests whether numbing a specific area (regional anesthesia) can reduce inflammation and pain during a sickle cell pain crisis. It may offer a new way to manage severe pain without strong medications.
This trial compares different ways to manage sickle cell pain crises in the hospital, using a flexible 'platform' design to test combinations of pain medicines. It aims to find the safest and most effective approach to reduce pain and improve recovery.
This trial tests an intravenous medicine called L-citrulline for young people with sickle cell disease who are in the emergency department for a painful crisis (vaso-occlusive crisis). It aims to see if it can ease the pain and help you recover faster.
This trial tests a new medicine, CSL889, for people with sickle cell disease who are currently having a pain crisis (vaso-occlusive crisis). The goal is to see if it safely helps reduce the pain and speed recovery.
Hear when a new Vaso-Occlusive Pain Episode in Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.